← All trials
NCT05831644
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 25, 2023
- Primary completion
- Jun 16, 2023
- Completion date
- Jun 20, 2023
- First posted
- Apr 26, 2023
- Last posted
- Aug 4, 2023
- Enrollment
- 11
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vicore Pharma ABLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.